Bachar Samra, MD

Hematologist/Oncologist @KelseySeybold | Clin. Asst. Prof. @UHouston | training via @LeukemiaMDA @SUNYdownstate @NorthwellHealth | Views = my own

[Bachar Samra, MD @BacharSamra]

Our new article➡️@BloodAdvances
Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse | https://t.co/74hzJaJ1y7 |
@DrHKantarjian @JoeKhouryMD @grichardmd @SibaElHussein @NicholasShortMD @NitinJainMD @MDAndersonNews

[PER @gotoPER]

Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer https://t.co/dIijDoQPMb

[Bachar Samra, MD @BacharSamra]

Happy to have moderated this #CME educational program on #FollicularLymphoma exciting updates. Thanks @gotoPER for the opportunity

[PER @gotoPER]

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed Refractory Follicular Lymphoma https://t.co/SEPPyIyHmm

[Bachar Samra, MD @BacharSamra]

@ASCOPost @ASCO my login is not working and I reached out to customer service in October! they replied they will fix it shortly but they have not yet nor have returned my emails. I am paying for a subscription that I can’t access. Please address

[Bachar Samra, MD @BacharSamra]

@lungoncdoc @cancerGRACE @ASCO @ConquerCancerFd Congrats Eric!

[Bachar Samra, MD @BacharSamra]

@HadidiSamer @UTSWMedCenter @utswcancer @UAMSMyeloma Congrats!

[Bachar Samra, MD @BacharSamra]

Great discussions and educational meeting @GreatDebatesCME Thanks for the opportunity to participate @JohnPLeonardMD @jaltmanmd @calliecoombsmd

[Jessica Altman, MD @jaltmanmd]

⁦@JohnPLeonardMD⁩ facilitating an outstanding lymphoma round table during ⁦@GreatDebatesCME⁩ heme malignancies meeting in sunny LA! #GDHeme

[Bachar Samra, MD @BacharSamra]

@ArndtVogel @myESMO Can you plz show the chemo benefit in MRD+ that supports the last statement in their conclusion?

[Ahmed Kotb @AhmedKo45911157]

🆕APS Criteria Updates
🔴Clinical: New focus on microvascular issues; thrombocytopenia added
👶Pregnancy: Early losses <10 weeks excluded; severe preeclampsia remains
🧪Lab: High-titer IgG prioritized; IgM excluded

#APS #Hematology #MedTwitter #ASH

[Bachar Samra, MD @BacharSamra]

@GhayasIssa Great news! Congrats!

[Bachar Samra, MD @BacharSamra]

@CarinHagberg @MDAndersonNews Devastating news! Rest in peace and condolences to the family

[Bachar Samra, MD @BacharSamra]

Honored to receive the #NCORP Certificate of Excellence for patient enrollments in @NCI Cancer Clinical Trials. #CommunityOncology #CancerDisparities #Minorities #CancerResearch

[Bachar Samra, MD @BacharSamra]

@AaronGoodman33 And when you deactivate/drop IM you can be “certified” in Heme/Onc??

[Bachar Samra, MD @BacharSamra]

The curves speak for themselves. What’s the NNTT with 5000+ patients?Stage 3 early breast Ca? Long term commitment and not negligent tox.
<2% iDFS added in stage 2. No benefit in pts who didn’t get chemo. 35% early discont. 20% discont d/t AEs. Only 20% still on Ribo after 3y

[NEJM @NEJM]

In patients with stage II or III early breast cancer, the addition of ribociclib to adjuvant hormonal therapy resulted in a significant improvement in 3-year invasive disease–free survival. Read the full results of the NATALEE phase 3 trial: https://t.co/NhAqPLN4xY

[Bachar Samra, MD @BacharSamra]

@WSJ Cust Ser unprofessional. Long term customer. Was offered discounted rate/y but kept charging non discounted rate. Requested refund and cancel subsc as clearly unreliable, was told refund takes 2 weeks..cancelled sub. Now I get an email that I’ll be charged again same rate

[Bachar Samra, MD @BacharSamra]

Thanks again for the opportunity. Great meeting and discussions

[Binaytara @binaytara]

Wonderful start to day 2 of #BTFBOAS Albuquerque with @BacharSamra (@Preshealth), Dr. Yubao Wang (@Lovelace_Health), and Dr. Matthew Fero (@UNMCCC)!

[Bachar Samra, MD @BacharSamra]

@LeukDocJZ My longest HMA VEN was 5 years and 1 month, relapsed 6 months ago and now on HMA Enasidenib…will see

[Bachar Samra, MD @BacharSamra]

Looking forward! #aml #mds #ASH23 updates @btfoundation thanks for the opportunity to participate

[Binaytara @binaytara]

Anticipating this session with @BacharSamra (@PresHealth), Dr. Yubao Wang (@Lovelace_Health), & Dr. Matthew Fero (@UNMCCC) at New Mexico Hematology & Breast Cancer Conference!
📍 Hotel Albuquerque At Old Town
🗓️ February 2-3, 2024
➡️ https://t.co/lQJCzzqkcb
#CME #ASH23 #SABCS23

[Bachar Samra, MD @BacharSamra]

@WCInvestor Can you provide the link?

[Bachar Samra, MD @BacharSamra]

Weird discussion paragraph @nejm #ASH23 #mmsm we know SOC is Len maintenance…but we didn’t randomize and we decided on maintenance DaraLen. Still, we think Trial “allows for interpretation of benefit of Dara across whole regimen..but relative contribution cannot be determined…

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH23 #mmsm a relevant discussion point @NEJM that caution the use of Dara-R maintenance based on this trial. This question cannot be answered with the study design

[Bachar Samra, MD @BacharSamra]

@RahulBanerjeeMD @OncBrothers @FiekeHoff @GKaurMD Do you skip D22 in 28d cycles?